Opinion: Maintenance of clinical remission in ANCA-associated vasculitis

Nature Reviews Rheumatology

Volumn 9, Issue 2, 2013, Pages 127-132

  Luqmani, Raashid ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ADALIMUMAB; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; THYMOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; GRANULOMATOSIS WITH POLYANGIITIS; HUMAN; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PLASMAPHERESIS; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULITIS; ARTICLE; DISEASE MANAGEMENT; DRUG COMBINATION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; METHOTREXATE; PLASMAPHERESIS; REMISSION INDUCTION;

EID: 84873411124     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.188     Document Type: Review

References (50)

1. Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310-317 (2009).
2. Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211-220 (2010).
3. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
4. Luqmani, R. A. et al. Classical versus non-renal Wegener's granulomatosis. Q. J. Med. 87, 161-167 (1994).
5. Direskeneli, H. et al. Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda. J. Rheumatol. 38, 1471-1479 (2011).
6. Koldingsnes, W., Gran, J. T., Omdal, R. & Husby, G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br. J. Rheumatol. 37, 659-664 (1998).
7. Nachman, P. H., Hogan, S. L., Jennette, J. C. & Falk, R. J. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J. Am. Soc. Nephrol. 7, 33-39 (1996).
8. Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488-494 (2011).
9. Luqmani, R. et al. Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatology (Oxford) 50, 697-702 (2011).
10. Jennette, J. C. et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. http://dx.doi.org/10. 1002/art.37715.
11. Basu, N. et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann. Rheum. Dis. 69, 1744-1750 (2010).
12. Langford, C. A., Talar-Williams, C., Barron, K. S. & Sneller, M. C. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum. 42, 2666-2673 (1999).
13. Slot, M. C., Tervaert, J. W., Boomsma, M. M. & Stegeman, C. A. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum. 51, 269-273 (2004).
14. Luqmani, R. A. et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87, 671-678 (1994).
15. de Groot, K., Gross, W. L., Herlyn, K. & Reinhold-Keller, E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin. Nephrol. 55, 31-38 (2001).
16. Hellmich, B. et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 66, 605-617 (2007).
17. de Groot, K. et al. EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670-680 (2009).
18. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351-361 (2005).
19. Jayne, D. R. et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 18(7) 2180-2188 (2007).
20. Flossmann, O. et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann. Rheum. Dis. 68, 1125-1130 (2009).
21. Metzler, C., Fink, C., Lamprecht, P., Gross, W. L. & Reinhold-Keller, E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 43, 315-320 (2004).
22. Bremer, J. P., Ullrich, S., Laudien, M., Gross, W. L. & Lamprecht, P. Methotrexate plus leflunomide for the treatment of relapsing Wegener's granulomatosis. A retrospective uncontrolled study. Clin. Exp. Rheumatol. 28 (1 Suppl. 57), 67-71 (2010).
23. Lapraik, C. et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford), 46, 1615-1616 (2007).
24. Pagnoux, C. et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med. 359, 2790-2803 (2008).
25. Harper, L. et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann. Rheum. Dis. 71, 955-960 (2012).
26. Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 304, 2381-2388 (2010).
27. Smith, R. M. et al. Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis Rheum. http://dx.doi.org/10.1002/art. 34583.
28. Cartin-Ceba, R. et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): a single-center ten-year experience. Arthritis Rheum. http://dx.doi.org/10.1002/art.34584.
29. Roubaud-Baudron, C. et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J. Rheumatol. 39, 125-130 (2012).
30. Stegeman, C. A., Tervaert, J. W., de Jong, P. E. & Kallenberg, C. G. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med. 335, 16-20 (1996).
31. Zycinska, K., Wardyn, K. A., Zielonka, T. M., Krupa, R. & Lukas, W. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. Eur. J. Med. Res. 14 (Suppl. 4) 265-267 (2009).
32. Koldingsnes, W. & Nossent, J. C. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J. Rheumatol. 30, 80-88 (2003).
33. Gayraud, M. et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum. 44, 666-675 (2001).
34. Guillevin, L., Le Thi Huong, D., Godeau, P., Jais, P. & Wechsler, B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br. J. Rheumatol. 27, 258-264 (1988).
35. Guillevin, L. et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 49, 93-100 (2003).
36. Tomasson, G., Grayson, P. C., Mahr, A. D., Lavalley, M. & Merkel, P. A. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis. Rheumatology (Oxford) 51, 100-109 (2012).
37. Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 542-548 (2012).
38. Wada, T., Hara, A., Arimura, Y., Sada, K. E. & Makino, H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J. Rheumatol. 39, 545-551 (2012).
39. McGregor, J. G. et al. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin. J. Am. Soc. Nephrol. 7, 240-247 (2012).
40. Guillevin, L. et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90, 19-27 (2011).
41. de Groot, K. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 52, 2461-2469 (2005).
42. Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36-44 (2003).
43. Booth, A. et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 15, 717-721 (2004).
44. Laurino, S., Chaudhry, A., Booth, A., Conte, G. & Jayne, D. Prospective study of TNFα blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol. Dial. Transplant. 25, 3307-3314 (2010).
45. Schmitt, W. H. et al. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 65, 1440-1448 (2004).
46. Birck, R. et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol. 14, 440-447 (2003).
47. Martinez, V. et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 58, 308-317 (2008).
48. Muso, E. et al. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan. Jpn J. Infect. Dis. 57, S17-S18 (2004).
49. Jayne, D. R. et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93, 433-439 (2000).
50. Walsh, M., Chaudhry, A. & Jayne, D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann. Rheum. Dis. 67, 1322-1327 (2008).